Blood cancer molecular assays
Transcription
Blood cancer molecular assays
Blood cancer molecular assays ALL (1) 10% Acute lymphoblastic leukemia MPN (1, 2) 39% CLL (1) Myeloproliferative neoplasms 27% Chronic lymphocytic leukemia AML (1) 24% Myeloid MPN Polycythemia vera, 41% (JAK2 V617F, 96%) Chronic myeloid leukemia t(9;22), 24% (BCR-ABL1, 95%) Acute myeloid leukemia Lymphoid AML Complex karyotype t(8;21) abn(11q23) 4% 3% 4% inv(16) 5% CLL Normal karyotype 45% abn(14q32) 4% +8q24 5% del(17p) 7% ALL del(6q) 3% t(10;14) t(11;14) 5% del(13q) 48% abn(12p13) 3.5% 6% abn(12q23) 6,5% t(9;22) 24% tri(8) 6% Diseases and genetic abnormalities del(11q22 -q23) 14% t(15;17) 7% del(17q) 8% Other 13% Essential thrombocythemia, 22% (JAK2 V617F, 55%) Idiopathic myelofibrosis, 13% (JAK2 V617F, 65%) tri(12) 19% abn chr 5&7 13% Diagnosis and prognosis biomarkers BCR-ABL1 mutations BCR-ABL1 JAK2 mutations MPL mutations PML-RARA RAS EVI1 BAALC MN1 NPM1 mutations WT1 FLT3 (ITDs or mutations) CEBPα MLL-partner genes RUNX1-RUNX1T1 CBFb-MYH11 Follow-up biomarkers BCR-ABL1 JAK2 V617F PML-RARA MLL-partner genes CBFb-MYH11 RUNX1-RUNX1T1 WT1 Targeted therapies and other treatments Imatinib mesylate (Gleevec®) Dasatinib (Sprycel®) Nilotinib (Tasigna®) Hydroxyurea (Hydrea®) Interferon Other treatments ATRA/Arsenic trioxide Aurora/FLT3 kinase inhibitor Other kinase inhibitors Farnesyl transferase inhibitors Proteasome inhibitors Immunotargeting Other treatments IgVH mutational status ZAP-70 & CD38 CLLU1 LPL t(1;14) 20% del(9q) 11% Other 15% BCR-ABL1 MLL-partner genes ETV6-RUNX1 TCF3-PBX1 SIL-TAL1 BCR-ABL1 MLL-partner genes ETV6-RUNX1 TCF3-PBX1 SIL-TAL1 Immunotargeting Anti-BCL2 Other treatments Imatinib mesylate (Gleevec®) Other kinase inhibitors Immunotargeting Other treatments References: 1. Incidence in the USA in 2011. Leukemia and Lymphoma Society Website www.leukemia-lymphoma.org 2. Kutti J., Ridell B. (2001) Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 49, 164 Sample & Assay Technologies Manufacturer: QIAGEN GmbH, QIAGEN Strasse 1, 40724 Hilden, Germany ipsogen kits are in-vitro diagnostic medical devices validated in molecular biology for the detection and/or quantification of biomarkers in the diagnosis and follow-up of patients with leukemia. For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor. Fabricant : QIAGEN GmbH, QIAGEN Strasse 1, 40724 Hilden, Allemagne Les produits ipsogen sont des dispositifs médicaux de diagnostic in vitro validés pour la détection et/ou la quantification en biologie moléculaire de biomarqueurs impliqués dans le diagnostic et le suivi de patients atteints de cancers du sang. Pour obtenir les dernières informations sur la licence et les clauses de responsabilité spécifiques aux produits, lire attentivement les instructions figurant dans les notices d’utilisation et/ou sur l’étiquetage des réactifs et dans le manuel d’utilisation du système. Les manuels des kits et manuels d’utilisation QIAGEN sont disponibles à l’adresse www.qiagen.com ou peuvent être sollicités auprès des Services techniques QIAGEN ou du distributeur local. Trademarks: QIAGEN®, ipsogen® (QIAGEN Group); Gleevec®, Tasigna® (Novartis AG); Sprycel®, Hydrea® (Bristol-Myers Squibb Oncology) 1075398 © 2013 QIAGEN, all rights reserved.